Corbus Pharmaceuticals (3371) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

3371 Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Corbus

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

3371 Stock 12 Month Forecast

Average Price Target

€32.57

▲(238.52% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Corbus Pharmaceuticals in the last 3 months. The average price target is €32.57 with a high forecast of €42.63 and a low forecast of €26.64. The average price target represents a 238.52% change from the last price of €9.62.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","43":"€43","13.75":"€13.75","23.5":"€23.5","33.25":"€33.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42.63123552,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€42.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.56552713333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€32.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.6445222,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€26.64</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,13.75,23.5,33.25,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.51,8.365479655384615,11.220959310769231,14.076438966153846,16.93191862153846,19.787398276923078,22.64287793230769,25.498357587692304,28.353837243076924,31.209316898461537,34.06479655384615,36.92027620923077,39.775755864615384,{"y":42.63123552,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.51,7.591194394871795,9.67238878974359,11.753583184615383,13.834777579487179,15.915971974358973,17.99716636923077,20.078360764102563,22.159555158974356,24.24074955384615,26.321943948717944,28.403138343589745,30.48433273846154,{"y":32.56552713333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.51,7.135732476923076,8.761464953846154,10.38719743076923,12.012929907692307,13.638662384615383,15.264394861538461,16.89012733846154,18.515859815384616,20.141592292307692,21.76732476923077,23.393057246153845,25.01878972307692,{"y":26.6445222,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.065,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.855,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.895,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.51,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€42.63

Average Price Target€32.57

Lowest Price Target€26.64

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andres Y. Maldonado

H.C. Wainwright

€31.09

Buy

223.13%

Upside

Reiterated

09/15/26

Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), BioMarin Pharmaceutical (BMRN)

Robert Driscoll

Wedbush

€26.64

Buy

176.97%

Upside

Reiterated

09/15/26

Wedbush Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Graig Suvannavejh

Mizuho Securities

€29.31

Buy

204.67%

Upside

Reiterated

09/14/26

Mizuho Securities Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)

Oliver McCammon

LifeSci Capital

€33.75

Buy

250.83%

Upside

Reiterated

09/14/26

Corbus Pharmaceuticals: Buy Rating Reaffirmed as CRB-913 Phase 1b Data Impress; $38 Price Target Maintained

Andy Hsieh

William Blair

―

Buy

―

Reiterated

09/14/26

Analysts' Top Healthcare Picks: Corbus Pharmaceuticals (CRBP), Definium Therapeutics (DFTX)

Brian Abrahams

RBC Capital

€31.97

Buy

232.36%

Upside

Reiterated

08/12/26

RBC Capital Sticks to Their Buy Rating for Corbus Pharmaceuticals (CRBP)

Jeff Jones

Oppenheimer

€46.18→€42.63

Buy

343.15%

Upside

Reiterated

08/07/26

Corbus Pharmaceuticals price target lowered to $48 from $52 at OppenheimerCorbus Pharmaceuticals price target lowered to $48 from $52 at Oppenheimer

Paul Jeng

Guggenheim

€39.97

Buy

315.46%

Upside

Reiterated

06/02/26

Corbus Pharmaceuticals (CRBP) Gets a Buy from Guggenheim

Maury Raycroft

Jefferies

€31.97→€29.31

Buy

204.67%

Upside

Reiterated

05/12/26

Corbus Pharmaceuticals price target lowered to $33 from $36 at JefferiesCorbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies

Unknown Analyst

B. Riley Securities

Not Ranked

B. Riley Securities

€24.87

Buy

158.51%

Upside

Reiterated

04/10/26

We reiterate our buy ratings on CRBP ($28 PT)

Biren Amin

Piper Sandler

€31.09→€45.3

Buy

370.85%

Upside

Reiterated

10/20/25

Piper Sandler Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andres Y. Maldonado

H.C. Wainwright

€31.09

Buy

223.13%

Upside

Reiterated

09/15/26

Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), BioMarin Pharmaceutical (BMRN)

Robert Driscoll

Wedbush

€26.64

Buy

176.97%

Upside

Reiterated

09/15/26

Wedbush Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Graig Suvannavejh

Mizuho Securities

€29.31

Buy

204.67%

Upside

Reiterated

09/14/26

Mizuho Securities Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)

Oliver McCammon

LifeSci Capital

€33.75

Buy

250.83%

Upside

Reiterated

09/14/26

Corbus Pharmaceuticals: Buy Rating Reaffirmed as CRB-913 Phase 1b Data Impress; $38 Price Target Maintained

Andy Hsieh

William Blair

―

Buy

―

Reiterated

09/14/26

Analysts' Top Healthcare Picks: Corbus Pharmaceuticals (CRBP), Definium Therapeutics (DFTX)

Brian Abrahams

RBC Capital

€31.97

Buy

232.36%

Upside

Reiterated

08/12/26

RBC Capital Sticks to Their Buy Rating for Corbus Pharmaceuticals (CRBP)

Jeff Jones

Oppenheimer

€46.18→€42.63

Buy

343.15%

Upside

Reiterated

08/07/26

Corbus Pharmaceuticals price target lowered to $48 from $52 at OppenheimerCorbus Pharmaceuticals price target lowered to $48 from $52 at Oppenheimer

Paul Jeng

Guggenheim

€39.97

Buy

315.46%

Upside

Reiterated

06/02/26

Corbus Pharmaceuticals (CRBP) Gets a Buy from Guggenheim

Maury Raycroft

Jefferies

€31.97→€29.31

Buy

204.67%

Upside

Reiterated

05/12/26

Corbus Pharmaceuticals price target lowered to $33 from $36 at JefferiesCorbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies

Unknown Analyst

B. Riley Securities

Not Ranked

B. Riley Securities

€24.87

Buy

158.51%

Upside

Reiterated

04/10/26

We reiterate our buy ratings on CRBP ($28 PT)

Biren Amin

Piper Sandler

€31.09→€45.3

Buy

370.85%

Upside

Reiterated

10/20/25

Piper Sandler Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ZVRAZevra Therapeutics

DFTXDefinium Therapeutics

HITIHigh Tide

DNLIDenali Therapeutics

MDWDMediwound

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Corbus Pharmaceuticals

3 Months

Andy HsiehWilliam Blair

Success Rate

6/13 ratings generated profit

Average Return

-1.79%

Copying Andy Hsieh's trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of -1.79% per trade.

1 Year

Andy HsiehWilliam Blair

Success Rate

4/13 ratings generated profit

Average Return

-14.85%

Copying Andy Hsieh's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -14.85% per trade.

2 Years

Andy HsiehWilliam Blair

Success Rate

0/13 ratings generated profit

Average Return

-31.06%

Copying Andy Hsieh's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -31.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

3371 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 3371 has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 3371 average Analyst price target in the past 3 months is 32.57.

Each month's total comprises the sum of three months' worth of ratings.

3371 Financial Forecast

3371 Earnings Forecast

Next quarter’s earnings estimate for 3371 is -€1.08 with a range of -€1.70 to -€0.65. The previous quarter’s EPS was -€1.61. 3371 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 3371 has Performed in-line its overall industry.

3371 Sales Forecast

Next quarter’s sales forecast for 3371 is €1.78M with a range of €0.00 to €8.90M. The previous quarter’s sales results were €0.00. 3371 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 3371 has Performed in-line its overall industry.

3371 Stock Forecast FAQ

What is DE:3371’s average 12-month price target, according to analysts?

Based on analyst ratings, Corbus Pharmaceuticals’s 12-month average price target is 32.57.

What is DE:3371’s upside potential, based on the analysts’ average price target?

Corbus Pharmaceuticals has 238.52% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Corbus Pharmaceuticals a Buy, Sell or Hold?

Corbus Pharmaceuticals has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Corbus Pharmaceuticals’s share price target?

The average share price target for Corbus Pharmaceuticals is 32.57. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €42.63 ,and the lowest forecast is €26.64. The average share price target represents 238.52% Increase from the current price of €9.62.

What do analysts say about Corbus Pharmaceuticals?

Corbus Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Corbus Pharmaceuticals?

To buy shares of DE:3371, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Corbus Pharmaceuticals (3371) Stock Forecast & Price Target

3371 Analyst Ratings

3371 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Corbus Pharmaceuticals

3371 Analyst Recommendation Trends

3371 Financial Forecast

3371 Earnings Forecast

3371 Sales Forecast

3371 Stock Forecast FAQ

Detailed List of Analyst Forecasts